• Loading stock data…

Long-Term Play

Could This Biotech Stock Get Bought For $5.5 Billion? Either Way I’m Buying It

On Friday May 24th, 2019 Novartis (NYSE: NVS) gained FDA approval of its gene therapy product " Zolgensma® " for spinal muscular atrophy (SMA), originally purchased from AveXis in 2018 for $8.7 … [Read more...] about Could This Biotech Stock Get Bought For $5.5 Billion? Either Way I’m Buying It

Bristol-Myers Squibb Positioned For Deep Penetration In the Multiple Myeloma Market

Introduction Bristol-Myers Squibb (NYSE: BMY) is a profitable global bio-pharmaceutical company targeting an array of serious diseases and unmet medical needs. Earlier this month BMY announced … [Read more...] about Bristol-Myers Squibb Positioned For Deep Penetration In the Multiple Myeloma Market

ADMP Follows Through on Filing A New Drug Application For Tadalafil Sublingual Tablets

Leave a comment and click here to subscribe for MS article alerts and our newsletter! Adamis Pharmaceutical (NASDAQ: ADMP), a speciality pharmaceutical company, upheld its commitment to file a new … [Read more...] about ADMP Follows Through on Filing A New Drug Application For Tadalafil Sublingual Tablets

Parallels Between Conatus ENCORE-PH Readout And Galectin Therapeutics Phase-2b Clinical-CX

leave a comment and click here to sub for MS article alerts and our newsletter  Introduction  MS noticed some insightful parallels between when Conatus Pharmaceuticals (Nasdaq: CNAT) … [Read more...] about Parallels Between Conatus ENCORE-PH Readout And Galectin Therapeutics Phase-2b Clinical-CX